EP1.16-34 Survival Analysis of Icotinib for Brain Metastases in EGFR Mutated Non-Small Cell Lung Cancer

Survival and treatment options are limited for patients with brain metastases arising from non-small cell lung cancer (NSCLC). The aim of this study is to investigate the efficacy and survival analysis icotinib treatment for brain metastasis in non-small cell lung cancer patients with EGFR mutation. We retrospectively reviewed NSCLC patients with brain metastases who were treated with icotinib, and the survival rate was calculated by Kaplan-Meier method and log-rank test was used to compare the survival rates. Univariate and multivariate factors for survival were analyzed by COX proportional hazards regression model. 116 cases of rain metastases in EGFR mutated non-small cell lung cancer were female, less than 60 years old and non-smoking patients predominant; COX multivariate analysis found that histologic subtype and EGFR gene subtype were independent prognostic factors for these patients. Icotinib showed promising efficacy in NSCLC patients with brain metastases. PFS and OS was longer in patients with adenocarcinoma than in those with a non-adenocarcinoma subtype. PFSand OS was longer in patients with EGFR common mutations than EGFR uncommon mutations.